CAS: 144689-24-7; 1-((2'-(1H-Tetrazol-5-yl)-[1,1'-Biphenyl]-4-yl)Methyl)-4-(2-Hydroxypropan-2-yl)-2-Propyl-1H-Imidazole-5-Carboxylic Acid

上下游产品

雅脉膜衣锭乙酯杂质 Ethyl 4-(1-Hydroxy-1-Methylethyl)-2-Propyl-1-{[2′-(1H-Tetrazol-5-yl)-1,1′-Biphenyl-4-Yl]Methyl}-1H-Imidazole-5-Carboxylate 144689-23-6
奥美沙坦酯 Olmesartan Medoxomil 144689-63-4
N-三苯甲基奥美沙坦乙酯 Ethyl 4-(1-Hydroxy-1-Methylethyl)-2-Propyl-1-[2'-(2-Triphenylmethyl-2H-Tetrazol-5-yl)Biphenyl-4-Yl]Methyl-1H-Imidazole-5-Carboxylate 172875-59-1
Ethyl 1-(2'-Cyanobiphenyl-4-yl)Methyl-4-(1-Hydroxy-1-Methylethyl)-2-Propylimidazole-5-Carboxylate 144690-96-0
N2-三苯甲基奥美沙坦酯 Trityl Olmesartan Medoxomil 1020157-01-0

奥美沙坦酯置于sodium Hydroxide体系中,用 甲醇,水 用作溶剂,化学反应 20.0H,以90%的收率获得奥美沙坦
参考文献:抗高血压药奥美沙坦酯相关物质的合成
标题:抗高血压药奥美沙坦酯相关物质的合成
摘要:奥美沙坦酯 1 是 Fda 批准用于治疗高血压的最新血管紧张素受体拮抗剂.在奥美沙坦酯的工艺开发过程中,观测到四种相关物质(杂质)以及最终的 Api.这些杂质被鉴定为奥美沙坦酸,4-乙酰奥美沙坦,5-乙酰奥美沙坦和脱氢奥美沙坦.目前的工作描述了所有这四种杂质的合成和表征.
Doi:10.3998/ark.5550190.0011.224

专利信息

专利号:US-10973847-B2
优先权日:2017-06-30
标题 :Core-to-surface polymerization for the synthesis of star polymers and uses thereof
发明人：JOHNSON JEREMIAH A; GOLDER MATTHEW R
权利人:MASSACHUSETTS INST TECHNOLOGY
摘要:Disclosed are methods, compositions, reagents, systems, and kits to prepare star polymers, as well as compositions and uses thereof. Various embodiments show that synthesis of these polymers contain low metal concentration to provide polymers for diverse biomedical applications including in vivo applications.

专利号:US-2008214637-A1
优先权日:2004-11-11
标题 :Process for the Synthesis of Tetrazoles
发明人：ANTONCIC LJUBOMIR; LUDESCHER JOHANNES
权利人:LEK PHARMACEUTICALS
摘要:A process for the synthesis of tetrazol derivative has been developed which starts from a tetrazole derivative where acidic hydrogen atom has been replaced by a protecting group and the deprotection is performed with a catalytic amount of organic acid and can proceed in an aqueous solvent.

专利号:US-10005720-B2
优先权日:2013-04-05
标题:Compounds useful for the treatment of metabolic disorders and synthesis of the same
发明人：SEXTON JONATHAN Z; BRENMAN JAY E; MUSSO DAVID L
权利人:NORTH CAROLINA CENTRAL UNIV; UNIV NORTH CAROLINA CHAPEL HILL
摘要:The present invention provides compounds of Formula (I): wherein variables X, Y, Z and R1 are as described herein. Some of the compounds described herein are glutamate dehydrogenase activators. The invention is also directed to pharmaceutical compositions comprising these compounds, uses of these compounds and compositions in the treatment of metabolic disorders as well as synthesis of the compounds.

专利号:US-8431712-B2
优先权日:2004-02-09
标 题 :Methods for the synthesis of pyridoxamine
发明人：KHALIFAH RAJA G; KEILITZ ROLAND; KOELLNER CHRISTOPH; DEGENHARDT THORSTEN; BRAND STEPHEN ROBERT
权利人:KHALIFAH RAJA G; KEILITZ ROLAND; KOELLNER CHRISTOPH; DEGENHARDT THORSTEN; BRAND STEPHEN ROBERT; NEPHROGENEX INC
摘要:The invention provides non-oxidative methods for the large scale manufacture of pyridoxamine (I) (4-aminomethyl-3-hydroxy-5-hydroxymethyl-2-methylpyridine): n nand salts thereof.n nThe invention also provides intermediate compounds for the synthesis of pyridoxamine, as well as compositions and methods for the treatment and/or prevention of conditions associated with the formation of post-Amadori advanced glycation end-products.

专利号:US-9981949-B2
优先权日:2008-12-01
标题 :Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine
发明人：AKIREDDY SRINIVASA RAO; BHATTI BALWINDER SINGH; CUTHBERTSON TIMOTHY J; DULL GARY MAURICE; MILLER CRAIG HARRISON; MITCHENER JR JOSEPH PIKE; MUNOZ JULIO A; OTTEN PIETER ALBERT
权利人:OYSTER POINT PHARMA INC
摘要:The present invention relates to the stereospecific synthesis of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine, its salt forms, and novel polymorphic forms of these salts.

专利号:US-2008287407-A1
优先权日:2003-12-10
标题 :Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use
发明人：GARVEY DAVID S; FANG XINQIN; KHANAPURE SUBHASH P; RANATUNGA RAMANI R; WEY SHIOW-JYI
权利人:NITROMED INC
摘要:The invention describes novel nitrosated and/or nitrosylated pyruvate compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated pyruvate compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one pyruvate compound and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one pyruvate compound, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating diseases resulting from oxidative stress, diabetes, reperfusion injury following ischemia, preservation of tissues, organs, organ parts and/or limbs.